Skip to main content
logo
Brii Biosciences Limited (HKG:2137)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
0.9600
-0.0700 (-6.80%)
Aug 27, 2026, 4:08 PM HKT

Brii Biosciences Financials Overview

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
34.8535.5549.9455.89122.2892.54
Revenue Growth
-1.96%-28.81%-10.66%-54.29%32.13%12.56%
Gross Profit
34.8535.5549.9455.89122.2892.54
Operating Income
-263.16-286.8-403.85-544.73-513.85-610.48
Net Income
-175.12-222.62-508.16-174.83-484.31-4,164
Earnings Per Share
-0.24-0.31-0.70-0.24-0.67-9.48
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
1,7691,9402,3202,6612,9973,355
Total Debt
6.188.9328.023.1612.6621.62
Net Cash (Debt)
1,7631,9312,2922,6582,9853,333
Net Cash Growth
-8.67%-15.78%-13.74%-10.96%-10.45%-
Net Cash Per Share
2.422.673.143.654.137.59

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
--338.81-372.89-594.01-496.28-879.46
Capital Expenditures
--1.66-3.23---1.03
Free Cash Flow
--340.46-376.12-594.01-496.28-880.49
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-755.10%-806.80%-808.74%-974.63%-420.22%-659.68%
Pretax Margin
-500.13%-624.98%-1026.08%-329.87%-400.54%-4528.85%
Profit Margin
-502.48%-626.26%-1017.63%-312.80%-396.07%-4499.41%
FCF Margin
--957.76%-753.20%-1062.81%-405.86%-951.45%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
18.4825.7113.4927.0138.77208.62